Compare Jumia Technologies AG - ADR (JMIA) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Smith & Nephew plc — how do they compare? Jumia Technologies AG - ADR trades at $6.45 (market cap $719.58M), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 17.4× Jumia Technologies AG - ADR's market cap, and Smith & Nephew plc pays a 2.65% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals.
| JMIA | SNN | |
|---|---|---|
Market Cap | $719.58M | $12.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $38.70 |
52-Week Low | $5.69 | $28.73 |
Enterprise Value | $666.68M | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA trades at $6.325, up 5.42% today, but technical indicators show a bearish trend with moving averages signaling sell. The company reported a net loss of $61.55 million in 2025, though revenue grew to $188.93 million and the net loss margin improved to -32.58%. Recent news highlights progress toward Q4 2026 breakeven and a $50 million capital raise.
The outlook remains speculative with persistent losses and high valuation ratios like P/B of 55.05, but analyst consensus is bullish with 71% buy ratings. Key risks include cash burn and competitive pressures, while catalysts include continued operating leverage and expansion initiatives.
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
